NICE Adds Arthritis Drugs To Fast Track Appraisal Pathway
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical and cost effectiveness of Rituxan, Orencia, Humira, and Arava to be evaluated under single technology appraisal process.
You may also be interested in...
NICE Says Sequential Use Of TNF Inhibitors To Treat RA Is Not Cost Effective
The agency, however, recommends use of Abbott's Humira, Wyeth's Enbrel and Johnson & Johnson's Remicade to treat RA.
NICE Says Sequential Use Of TNF Inhibitors To Treat RA Is Not Cost Effective
The agency, however, recommends use of Abbott's Humira, Wyeth's Enbrel and Johnson & Johnson's Remicade to treat RA.
Cancer Drugs Move To NICE's Fast-Track Appraisal Process
Guidances for some products could be issued by the end of the year under a new rapid review system.